about
Human pluripotent stem cell-derived products: advances towards robust, scalable and cost-effective manufacturing strategies.Data mining for rapid prediction of facility fit and debottlenecking of biomanufacturing facilities.Capacity planning for batch and perfusion bioprocesses across multiple biopharmaceutical facilitiesAdvanced multivariate data analysis to determine the root cause of trisulfide bond formation in a novel antibody-peptide fusionEstablished bioprocesses for producing antibodies as a basis for future planning.Integrated economic and experimental framework for screening of primary recovery technologies for high cell density CHO cultures.Multi-criteria manufacturability indices for ranking high-concentration monoclonal antibody formulations.Representative mammalian cell culture test materials for assessment of primary recovery technologies: a rapid method with industrial applicability.Allogeneic cell therapy bioprocess economics and optimization: single-use cell expansion technologiesDecisional tool to assess current and future process robustness in an antibody purification facility.A scale-down mimic for mapping the process performance of centrifugation, depth and sterile filtration.Designing cost-effective biopharmaceutical facilities using mixed-integer optimization.Strategic biopharmaceutical portfolio development: an analysis of constraint-induced implications.Optimising the design and operation of semi-continuous affinity chromatography for clinical and commercial manufacture.On-Line Control of Glucose Concentration in High-Yielding Mammalian Cell Cultures Enabled Through Oxygen Transfer Rate Measurements.A roadmap for cost-of-goods planning to guide economic production of cell therapy products.An integrated experimental and economic evaluation of cell therapy affinity purification technologies.An automated laboratory-scale methodology for the generation of sheared mammalian cell culture samples.Multiobjective long-term planning of biopharmaceutical manufacturing facilities.Medium term planning of biopharmaceutical manufacture with uncertain fermentation titers.A computer-aided approach to compare the production economics of fed-batch and perfusion culture under uncertainty.Combining multiple quantitative and qualitative goals when assessing biomanufacturing strategies under uncertainty.Process change evaluation framework for allogeneic cell therapies: impact on drug development and commercialization.Decision-support tool for assessing biomanufacturing strategies under uncertainty: stainless steel versus disposable equipment for clinical trial material preparation.A software tool to assist business-process decision-making in the biopharmaceutical industry.Application of quality by design principles to the development and technology transfer of a major process improvement for the manufacture of a recombinant protein.Allogeneic cell therapy bioprocess economics and optimization: downstream processing decisions.A tool for modeling strategic decisions in cell culture manufacturingA Software Tool to Assist Business-Process Decision-Making in the Biopharmaceutical IndustryWindows of operation for bioreactor design for the controlled formation of tissue-engineered arteriesPotential of Continuous Manufacturing for Liposomal Drug ProductsMultivariate Data Analysis Methodology to Solve Data Challenges Related to Scale-Up Model Validation and Missing Data on a Micro-Bioreactor SystemIntegrated Continuous Biomanufacturing: Industrialization on the HorizonHigh throughput process development workflow with advanced decision-support for antibody purificationBenchmarking biopharmaceutical process development and manufacturing cost contributions to R&D
P50
Q30395748-5514AA51-527D-4489-9B7B-8EB3478DEA00Q30779814-4C6EDE96-752E-4C25-88E3-20501EC76EEAQ35557018-0B364D56-AB63-458D-BA34-820EFEA2BC88Q36370910-9D91507D-8BBC-482E-94CC-7A130D757AABQ36600084-EBF58B22-98E1-4D5A-8B4B-9327F25570A8Q38779164-92E50220-D81E-4309-8E78-1C63ACB9019AQ38808725-9E08256A-8311-4F38-AB66-996A057A3B78Q38942131-79BF9362-C830-44F4-80AC-995166DCB2E8Q39376650-3DB9B79B-6C31-44C5-8594-A29C671A5B89Q39612110-925CEE88-E558-40E3-A086-58B341188772Q41137596-800AA5B1-C242-4EE7-AC2E-ABFEC9EF8847Q45876063-2EF27CFB-BFC4-4BBA-AA57-610E0890C392Q45964622-E3954F4F-7C14-4477-842B-58B7B16D28B8Q46072831-A789ADB4-2B0A-4AB7-83ED-1C15FA6E50E1Q47244159-B8BAA575-F3D3-4924-B9A9-855296C46781Q47650212-D649C804-D180-451E-B7D5-4ADBDCEF5261Q48012990-08982001-6963-4DA7-9636-4BA48D04BC86Q50875252-2358BC92-3CBE-47A2-96C5-C7CD84DD33DAQ50893900-E14A3F5C-3831-4DBC-8CB7-5BD0001E8318Q51099282-6761503A-20B3-4841-AD1B-83393BD5F594Q51328018-2A0FFEDE-72BA-4A32-B4F4-E58019155A15Q51379142-2D62A244-CF43-4DB9-A737-96824590CAE4Q51442619-F925FFDC-301D-403B-BAE0-5F7907B7B205Q51514733-236EC48C-BD02-434D-90C2-F1EBC5E62FFBQ51635023-4A5AB0B7-5A74-48E8-A967-2A56D80A6AC3Q51765016-F798A5C5-71F1-48C1-BFFC-C404B8E6DCC5Q51823214-9ECDDBEC-BB9B-4B49-8EAA-1AA7E4F45FB6Q73066437-C12334FD-9F59-4047-ACCC-CAE8D44B6046Q81780351-6587A295-0CDD-4F56-AF3F-8D3CF567A725Q83740139-2D1FBD1B-46FC-4CF9-875B-D1F8FE1808B5Q88748038-4210A082-0C81-49C2-A58B-0E593ABB4F35Q90741523-A3E5C5C6-5FC2-4B12-8677-F157D7F66429Q91394652-E0BCF99C-DCCA-4B15-A764-0E1B243553B9Q92454839-C36A2D41-C020-4FC1-B942-D9973B029D50Q95657969-5A64DD46-4E33-4326-A7DC-C87EE19AA7A3
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Suzanne S Farid
@nl
Suzanne S Farid
@sl
Suzanne S. Farid
@en
Suzanne S. Farid
@es
type
label
Suzanne S Farid
@nl
Suzanne S Farid
@sl
Suzanne S. Farid
@en
Suzanne S. Farid
@es
prefLabel
Suzanne S Farid
@nl
Suzanne S Farid
@sl
Suzanne S. Farid
@en
Suzanne S. Farid
@es
P1053
C-2473-2008
P106
P1153
7005343335
P21
P31
P3829
P496
0000-0001-8155-0538